Market Trends Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3GBy admin8996erT0allMarch 21, 2025 TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS) Thursday said that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration…
Market Trends Kidney disease drug developer Maze files for $100M IPO (IPO:NYSEARCA)By admin8996erT0allJanuary 8, 2025 2d illustrations and photosMaze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through…
